NCTR changes leaders
This article was originally published in The Tan Sheet
Executive Summary
William Slikker, Jr. is the new acting director of FDA's National Center for Toxicological Research, the agency announces Jan. 3. He replaces Don Casciano, who served as NCTR director for six years and will move to the private sector. Slikker, who is a member of the Teratology Society and the Society of Toxicology, is an adjunct professor in the the Department of Pharmacology & Toxicology at the University of Arkansas, and as associate editor of the journals NeuroToxicology and Toxicological Sciences. He most recently served as NCTR's Deputy Center Director for Research...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.